Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic InFuse PMA Approval Sets Up CMS “New Technology” Add-On

This article was originally published in The Gray Sheet

Executive Summary

FDA's July 2 approval of Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system arrives in time for the device to qualify for a Medicare "new technology" add-on payment

You may also be interested in...



Medtronic’s Restore, W.L. Gore’s Tag Receive New Tech Add-On Payment

Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007

Medtronic’s Restore, W.L. Gore’s Tag Receive New Tech Add-On Payment

Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007

Medtronic “Grooves Its Swing” With Widened InFuse Use, Cervical Disc Prep

FDA likely will require Medtronic Sofamor Danek to perform PMA clinical trials of multilevel fusion indications for its Bryan and Prestige artificial cervical discs, the company says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel